Writing Group Disclosures
Writing Group Member	Employment	Research Grant	Other Research Support	Speakers' Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Kiran Musunuru	Harvard University	None	None	None	None	None	None	None
Kathleen T. Hickey	Columbia University	None	None	None	None	None	None	None
Sana M. Al-Khatib	Duke University Medical Center	None	None	None	None	None	None	None
Christian Delles	University of Glasgow	European Commission†	None	None	None	None	None	None
Myriam Fornage	University of Texas Health Science Center at Houston	None	None	None	None	None	None	None
Caroline Fox	NHLBI	None	None	None	None	None	None	None
Lorraine Frazier	University of Arkansas for Medical Sciences	None	None	None	None	None	None	None
Bruce D. Gelb	Icahn School of Medicine at Mount Sinai	Shire†	None	None	None	None	None	Royalties for PTPN11, SOS1, RAF1, and SHOC2 gene testing for Noonan syndrome from GeneDx* and Correlegan*; LabCorp*; Preventive Genetics*; Baylor College of Medicine*; Harvard Partners*
David M. Herrington	Wake Forest School of Medicine	NIH†	None	None	None	None	None	None
David E. Lanfear	Henry Ford Health System	None	None	None	None	None	None	None
Jonathan Rosand	Massachusetts General Hospital	NIH/NINDS†	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

^*

Modest.

^†

Significant.